穿孔素
K562细胞
白细胞介素21
脱颗粒
颗粒酶B
白细胞介素12
颗粒酶
CD16
生物
淋巴因子激活杀伤细胞
NK-92
Janus激酶3
细胞毒性
细胞毒性T细胞
细胞生物学
自然杀伤细胞
免疫学
CD8型
免疫系统
CD3型
体外
生物化学
白血病
受体
作者
Rebecca A. Nickle,Lisa Chou,Sam Bhattacharya,Miguel A. Tam,Carsen Wiethe
出处
期刊:Journal of Immunology
[American Association of Immunologists]
日期:2023-05-01
卷期号:210 (Supplement_1): 73.11-73.11
标识
DOI:10.4049/jimmunol.210.supp.73.11
摘要
Abstract Natural Killer (NK) cell-mediated cytotoxicity is a critical mechanism of the immune system to respond against harmful stimuli. The development of emerging cell therapies, such as CAR-NK cells, requires a deeper characterization of cultured NK cells. Here we show a phenotyping of ex vivo and in vitro NK cells, and demonstrate how high quality and reliable reagents from BioLegend ensure a more in depth cytotoxic analysis. NK cells were isolated from fresh human PBMCs, using our MojoSort™ Human NK Cell Isolation Kit, and incubated at different ratios with Tag-it Violet™ stained K562 target cells in IMDM + BioLegend’s Cell-Vive™ T-NK Xeno-Free Serum Substitute, in the presence of CD107a-PE. Cells were then harvested for surface phenotyping and the supernatants were collected for cytokine analysis using LEGENDplex™ Human CD8/NK Panel. Tag-it Violet™ and Apotracker™ Green staining of K562 cells demonstrate significant decrease in proliferation and significant increase in apoptosis, respectively. Surface staining of CD107a reveals increased degranulation of both CD56bright CD16− and CD5 + CD16+ NK cells that correlates with increased apoptosis of K562 cells. Supernatant cytokine analysis revealed significant increases in Granzyme A and B, Perforin, and Granulysin, among others. Taken together, these results show a more complete picture of the phenotypical and functional state of NK cells by measuring target cell killing as well as characterizing NK surface markers and secreted molecules involved in NK-mediated cytotoxicity. BioLegend reagents are designed to address ever increasing needs for deeper understanding of immunological processes and support the demand to develop sophisticated and consistent cell-based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI